Johnson & Johnson (JNJ) is back in focus after releasing detailed IMAAVY data in generalized myasthenia gravis at the European Academy of Neurology Congress, which reinforces interest in its autoimmune portfolio and stock.

IMAAVY’s new gMG data lands at a time when Johnson & Johnson’s share price has strong momentum, with a 1-month share price return of 14.81% and a year-to-date share price return of 28.88%. The 1-year total shareholder return of 75.82% points to strong gains over both shorter and longer horizons.

If you are looking beyond Johnson & Johnson for other healthcare opportunities, this may be a good moment to scan companies benefiting from similar themes in immunology and neurology through the 40 healthcare AI stocks

After a 1 month gain of 14.81% and a share price above the average analyst target of US$257.95, yet still screening at an estimated 32% discount to intrinsic value, is the market being too cautious on Johnson & Johnson, or simply disciplined on what it will pay for this story?

Most Popular Narrative: 8.4% Overvalued

Compared with Johnson & Johnson's last close of $267.24, the most followed narrative fair value of $246.46 implies a modest premium in the current price.

Johnson & Johnson represents a high-quality, defensive healthcare leader with resilient earnings, strong cash flow generation, and disciplined capital allocation. Following the Kenvue spin-off, JNJ is now more focused on higher-margin Pharmaceutical and MedTech segments, improving long-term growth visibility.

Curious what underpins that fair value for Johnson & Johnson? The narrative leans on steady revenue expansion, firm margins, and a future earnings multiple that assumes ongoing pricing power.

Result: Fair Value of $246.46 (OVERVALUED)

However, Johnson & Johnson still faces potential pressure from litigation exposures and product pipeline setbacks, which could challenge current assumptions around margins and fair value.

Another View: Johnson & Johnson Through the Cash Flow Lens

While the popular narrative pegs Johnson & Johnson as 8.4% overvalued at a fair value of $246.46, the SWS DCF model points in the opposite direction, with a future cash flow value estimate of $390.47. That suggests the current $267.24 price could be leaving a wide gap on the table, or simply reflecting more conservative real world expectations. Which story do you trust?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Johnson & Johnson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on Johnson & Johnson’s valuation and sentiment, this is a good moment to review the data, weigh both risk and reward factors, and see how the story fits your own framework with the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Johnson & Johnson?

If Johnson & Johnson has your attention, do not stop there. Broaden your watchlist with other stocks that fit clear, evidence based criteria using focused screeners.

• Target dependable income by scanning companies that meet strict yield and resilience tests through the 9 dividend fortresses
• Hunt for quality at a sensible price with the 45 high quality undervalued stocks to spot stocks combining strong fundamentals with appealing valuations
• Prioritize capital preservation by filtering for companies that pass tough stability checks via the 74 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.